Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial

  1. Twelves, C.
  2. Cortés, J.
  3. O'Shaughnessy, J.
  4. Awada, A.
  5. Perez, E.A.
  6. Im, S.–A.
  7. Gómez-Pardo, P.
  8. Schwartzberg, L.S.
  9. Diéras, V.
  10. Yardley, D.A.
  11. Potter, D.A.
  12. Mailliez, A.
  13. Moreno-Aspitia, A.
  14. Ahn, J.-S.
  15. Zhao, C.
  16. Hoch, U.
  17. Tagliaferri, M.
  18. Hannah, A.L.
  19. Rugo, H.S.
Revista:
European Journal of Cancer

ISSN: 1879-0852,  0959-8049

Ano de publicación: 2017

Volume: 76

Páxinas: 205-215

Tipo: Artigo

DOI: 10.1016/J.EJCA.2017.02.011 GOOGLE SCHOLAR lock_openAcceso aberto editor

Obxectivos de Desenvolvemento Sustentable

Fonte de datos: Scopus